Byotrol PLC
04 June 2007
BYOTROL NEW GLOBAL CONTRACT ANNOUNCEMENT
The Directors of Byotrol plc (the 'Company') are pleased to be able to report a
new global contract that has been secured by the Company.
The Company has worked in partnership to develop a range of products
incorporating Byotrol(R) technology for Fellowes Inc, a leading global provider
of office accessories and business machines.
As a global provider, Fellowes has access to a wide range of disinfectant
technologies and chose Byotrol for its residual efficacy, ultra low toxicity
profile and broadband action against a wide range of micro-organisms.
Fellowes is launching the Virashield(TM) range of products containing Byotrol
across Europe with a global launch planned in the near future. The range, which
includes wipes and hand protection foam, is designed to help combat the spread
of infections in the workplace. Virashield(TM) offers both residual efficacy of
up to seven days coupled with broad spectrum capability against a wide range of
organisms including viruses such as influenza and avian flu and bacteria
including E.coli. Research has shown that a typical office desk harbours up to
400 times more bacteria than a typical toilet seat and the residual efficacy
offered by the Virashield range containing Byotrol will help office workers
combat this real and growing risk of infection.
The Virashield(TM) range has been extensively tested by both Byotrol and
Fellowes and the tests have proven the product's efficacy for up to seven days
following application. The range can both remove microbes from surfaces in an
office environment and keep the surface microbially clean for this period of
time.
Byotrol plc Chief Executive David McRobbie said, 'We are delighted to have
secured our first contract that will make Byotrol available on a global basis
and that a company the size of Fellowes chose Byotrol as its worldwide strategic
partner for this key product launch. There is growing awareness that
micro-organisms are not just an issue in hospitals and specialist environments
and that effective cleaning regimes have a role in a wider range of settings.'
Headquartered in Illinois, USA with subsidiaries in Canada, Benelux, France,
Germany, Italy, Poland, Spain, UK, China, Singapore, Japan, Korea and Australia,
they have an extensive distribution & export network reaching over 100
countries. Fellowes employs more than 2,700 people throughout the world and
expects global sales in excess of $700 million this year.
Enquiries:
Byotrol plc 0161 277 9518
Stephen Falder Deputy Chairman
Richard Bell 07825 204 110
Finance Director
Charles Stanley Securities 020 7149 6457
Philip Davies
McCann Erickson PR 01625 822540
Jim Rothnie
Rawlings Financial 01756 770376
John Rawlings
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.